Public Sector Pension Investment Board raised its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 27.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 121,154 shares of the company's stock after purchasing an additional 25,802 shares during the quarter. Public Sector Pension Investment Board owned about 0.21% of Harmony Biosciences worth $4,021,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently bought and sold shares of the business. Nuveen LLC acquired a new position in Harmony Biosciences in the first quarter valued at $3,805,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Harmony Biosciences in the first quarter valued at $3,791,000. Citigroup Inc. increased its stake in Harmony Biosciences by 2.8% in the first quarter. Citigroup Inc. now owns 205,340 shares of the company's stock valued at $6,815,000 after purchasing an additional 5,539 shares during the period. Swiss National Bank increased its stake in Harmony Biosciences by 6.0% in the first quarter. Swiss National Bank now owns 82,900 shares of the company's stock valued at $2,751,000 after purchasing an additional 4,700 shares during the period. Finally, LSV Asset Management increased its stake in Harmony Biosciences by 25.0% in the first quarter. LSV Asset Management now owns 1,194,961 shares of the company's stock valued at $39,661,000 after purchasing an additional 238,744 shares during the period. 86.23% of the stock is currently owned by institutional investors and hedge funds.
Harmony Biosciences Price Performance
HRMY stock traded up $0.28 during trading on Friday, reaching $37.57. 152,392 shares of the company were exchanged, compared to its average volume of 652,199. The company has a market cap of $2.16 billion, a P/E ratio of 12.11, a PEG ratio of 0.43 and a beta of 0.84. Harmony Biosciences Holdings, Inc. has a 52-week low of $26.47 and a 52-week high of $41.61. The stock's 50 day moving average price is $34.37 and its 200 day moving average price is $33.70. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.80 and a current ratio of 3.84.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.78 by ($0.10). The business had revenue of $200.49 million for the quarter, compared to analyst estimates of $204.37 million. Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%.The business's revenue was up 16.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.05 EPS. Harmony Biosciences has set its FY 2025 guidance at EPS. As a group, analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
HRMY has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and issued a $55.00 target price (up previously from $54.00) on shares of Harmony Biosciences in a report on Thursday, July 10th. Truist Financial initiated coverage on shares of Harmony Biosciences in a report on Monday, July 21st. They issued a "buy" rating and a $48.00 target price on the stock. UBS Group lowered their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Monday, April 28th. Cantor Fitzgerald raised shares of Harmony Biosciences to a "strong-buy" rating in a report on Tuesday, May 13th. Finally, The Goldman Sachs Group initiated coverage on shares of Harmony Biosciences in a report on Thursday, July 10th. They issued a "neutral" rating and a $33.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Harmony Biosciences currently has a consensus rating of "Buy" and a consensus price target of $51.00.
Read Our Latest Stock Report on Harmony Biosciences
Harmony Biosciences Profile
(
Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Read More
Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
